Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Sezary Syndrome 2Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Hepatitis 1Graft vs Host Disease 1Colitis 1Bronchiolitis Obliterans Syndrome 1

Interventions

pembrolizumab 1282Specimen Handling 927Carboplatin 836Magnetic Resonance Spectroscopy 834Cyclophosphamide 807Cisplatin 735Nivolumab 680Paclitaxel 635Radiotherapy 617Gemcitabine 580Biopsy 559Bevacizumab 485Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 361Fluorouracil 357atezolizumab 350durvalumab 340Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 319Blood Specimen Collection 317Standard of Care 311Pemetrexed 307Ipilimumab 303Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Photopheresis × 1 year × Clear all
NCT07619898 2026-06-02

PHOENIX-ECP

Therakos LLC

Phase 2 Not yet recruiting
112 enrolled
Dermatologic

Colitis, Hepatitis, Melanoma

NCT05157581 2025-12-30

ECP

University of Pittsburgh

Recruiting
20 enrolled
Lymphoid

Sezary Syndrome

NCT04930653 2025-10-14

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

City of Hope Medical Center

Phase 2 Recruiting
34 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡